

Join Eurordis advocacy! The Drug Information, Transparency and Access Task Force

An Eurordis task force of volunteers



This activity is funded by the Health
Programme of the European Union

Regulation of medicines =

Pilot projects, mentoring, PCWP

How to conduct clinical trials in the EU?

Single arm trials vs Placebo controlled?
Role of patients in the design and conduct of trials?

ACT EU, ICH guidelines, CTIS

Patient Experience Data

Patient engagement, Patient Preferences Elicitations studies, Patient data...

EMA Reflection Paper, IHI projects...

Involvement in EMA decision-making

Early Dialogue CHMP, Scientific Advisory Groups, Oral explanation, document review, Col...

Patient information

Electronic package leaflet, risk minimisation measures / patient card, medicines overviews, campaign label use

Web-RADR app, SCOPE JA,

Shortages of medicines

Analysis of causes, information to patients catalogues, risk assessment plans, impact for patients, of critical medicines

Common Position 45 organisations, list of proposals, CMA

And much more!

Pilot for drug repurposing, Big data, AI, raw data, EMA communication, third party contributions...



This activity is funded by the Health Programme of the European Union

Karen Druckman, SWI
Hereditary Hemorrhagic Telangiectasia



Ilaria Galetti, ITA
Systemic sclerosis (FESCA)



Irena Bibic, CRO
Dravet Syndrome



Alan Timothy, GBR
rare lung diseases



Russell Wheeler, GBR / FRA
Leber's Hereditary Optic Neuropathy



Evy Reviere, BEL
Amyotrophic lateral scl.



Florian Innig, GER
Achondroplasia



Michela Onali, ITA
GNE myopathies



Daniel de Vicente, SPA
Niemann-Pick B



Janet Bloor, GBR
Duchenne UK and RACC



Jean-Ch. Fidalgo, FRA
Amyloidosis



And
Kees Deijl, NLD

About the task force

- Members are appointed by the Board of Directors
 - As they contribute shaping Eurordis positions
- For a mandate of 3 years
- We meet every month online (90 minutes)
 - And once a year face-to-face
- Members participate in conferences and can volunteer to EMA working groups
- Anne-Mary Bodin is coordinating organisational aspects and reports
- All minutes are public
- Next call: June 2025!
 - Summer School participants
 - Or if you express your interest!



This activity is funded by the Health Programme of the European Union

Your objectives

Development and implementation of new legislations: your opinion?

Awareness of patients / authorisation and use of medicines (committees, WPs...)

Guidance documents

Advice in relation to product-specific matters – excepted confidential information

Transparency of the regulatory procedures, involvement of patients

Information on access to medicines (i.e. compassionate use, placing on the market)



This activity is funded by the Health
Programme of the European Union

Thank you!

François Houyez, Director of Treatment Information
and Access, EURORDIS

francois.houyez@eurordis.org



This activity is funded by the Health
Programme of the European Union